The results in Figure 4D demonstrated that the CD33+ CD123+ primary AML-M4 blasts were specifically killed (up to 90% at 1:1), while only 60% of CD33+ CD123+ primary AML-M5 blasts were eliminated by both CD33 and CD123 CAR NK cells at 3:1 and 1:1 ratios, respectively. The gene discussed is CD33; the disease is acute myeloid leukemia.